Supplied as a lyophilised powder for research use, AOD-9604 maintains the receptor activity associated with metabolic investigation while excluding the full-length HGH structure
The neuroprotective properties of this nootropic agent help protect neurons from lactocidosis by preventing the formation of free radicals and have been studied in Parkinsons disease, Alzheimers disease, MS, ALS, TBI, and stroke
Sleep more than you'd like to admit you need
RS-2023-00285353 (K.M.K.)] and the Basic Science Research Program through the NRF funded by the Ministry of Education [No
Key selective action features: No Growth Hormone Receptor Binding: Does not activate GH receptors responsible for IGF-1 stimulation and systemic growth effects Preserved Glucose Metabolism: No impact on blood sugar regulation, insulin sensitivity, or diabetic risk markers No Tissue Growth Effects: Does not promote muscle hypertrophy, organ growth, or cell proliferation pathways Adipose-Specific Targeting: Works primarily through beta-3 adrenergic receptors concentrated in fat tissue No IGF-1 Elevation: Clinical trials confirmed no changes in serum IGF-1 levels at therapeutic doses Isolated Lipolytic Action: Maintains the fat-breaking properties of growth hormone fragment 176-191 without broader effects Selective Mechanism: Structural differences from full-length GH prevent binding to receptors mediating non-fat-related effects Clinical Validation: Human studies in 900+ participants confirmed selective fat metabolism without systemic hormonal changes The following guide provides detailed analysis of AOD-9604 s selective action and why this selectivity matters for safe, targeted fat metabolism
